S‐adenosyl methionine as monotherapy showed no clear difference in acceptability Participants dropping out of treatment during the… compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether S‐adenosyl methionine as monotherapy changes acceptability Participants dropping out of treatment during the… compared with tricyclic antidepressant agent (very low certainty).
Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).
It is very uncertain whether adjunctive lithium + antipsychotics changes acceptability of treatment leaving early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
Lithium as sole treatment showed no clear difference in acceptability of treatment leaving early due to any reason compared with placebo (low certainty).
It is very uncertain whether lithium changes acceptability of treatment leaving early due to any reason compared with antipsychotics (very low certainty).
Peribulbar showed no clear difference in acceptability of blocks compared with retrobulbar (moderate certainty).
It is very uncertain whether paroxetine changes treatment acceptability compared with placebo (very low certainty).
DCS and cognitive and behavioural therapies showed no clear difference in treatment acceptability: withdrawals from treatment compared with placebo and cognitive and behavioural therapies (moderate certainty).
It is very uncertain whether DCS and cognitive and behavioural therapies changes treatment acceptability: withdrawals from treatment compared with placebo and cognitive and behavioural therapies (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether morita therapy plus pharmacological therapy changes acceptability drop‐outs for any reason compared with pharmacological therapy alone (very low certainty).
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).